SCHEMBL4407809

SCHEMBL4407809

CCOc1cccc(N2Cc3cnc(NC4CCC(N)CC4)nc3N(CC)C2=O)c1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 3/20 0.40
MAP4K2 Q12851 3/20 0.40
CDK1 P06493 3/20 0.40
CDK4 P11802 3/20 0.40
CCND1 P24385 3/20 0.40
CDK2 P24941 3/20 0.40
EGFR P00533 1/20 0.39
CSF1R P07333 1/20 0.39
MAPK8 P45983 1/20 0.38
MAPK10 P53779 1/20 0.38
FGFR4 P22455 8/20 0.38
MAPK7 Q13164 1/20 0.37
FGFR1 P11362 2/20 0.37
MAPK14 Q16539 1/20 0.37
CDK7 P50613 1/20 0.36
CDK9 P50750 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
FGFR2 P21802 1/20 0.36
FGFR3 P22607 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4411322 0.94 EGFR (0.45) TNK2MAP4K2CDK1CDK4CCND1
SCHEMBL4414355 0.92 MAPK14 (0.46) TNK2MAP4K2CDK1CDK4CCND1
SCHEMBL4406372 0.91 TNK2 (0.40) TNK2MAP4K2CDK1CDK4CCND1
SCHEMBL4407018 0.90 EGFR (0.46) TNK2MAP4K2CDK1CDK4CCND1
SCHEMBL4411380 0.88 EGFR (0.45) TNK2MAP4K2CDK1CDK4CCND1
SCHEMBL4406742 0.87 FGFR4 (0.42) MAP4K2CDK1CDK4CCND1CDK2
SCHEMBL4396596 0.86 FGFR4 (0.42) MAPK8MAPK10FGFR4FGFR1MAPK14
SCHEMBL4405431 0.85 EGFR (0.47) TNK2MAP4K2CDK1EGFRCSF1R
SCHEMBL4411160 0.85 FGFR4 (0.46) FGFR4FGFR1FGFR2FGFR3
SCHEMBL4405803 0.84 EGFR (0.44) TNK2MAP4K2EGFRCSF1RFGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549651-B1 PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS WARNER LAMBERT CO (US) 2009-12-23 EP disclosed
US-7196090-B2 Kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-03-27 US disclosed
EP-1549651-A1 KINASE INHIBITORS Warner-Lambert Company LLC (US) 2005-07-06 EP disclosed
WO-2004011465-A1 KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-05 WO disclosed
US-20040019210-A1 Kinase inhibitors CHIVIKAS CONNOLLY CLEO J (US) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019210-A1 Kinase inhibitors CDK2, CDK1, CDK4 TNK2 140/4885MAP4K2 54/4885CDK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.